title: Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B.
abstract: Chronic hepatitis B virus (HBV) is a serious and life-threatening disease afflicting 350 million of the world's population. So far, current monotherapy with conventional interferon-alpha, lamivudine, and adefovir dipivoxil remains unsatisfactory. In addition, the use of conventional interferon-alpha needs to be administered subcutaneously daily or thrice weekly and is associated with frequent adverse events. Although nucleoside-nucleotide analogs such as lamivudine and adefovir dipivoxil are well tolerated and can normalize serum alanine aminotransaminase rapidly, 1-year therapy with either lamivudine or adefovir dipivoxil results in low hepatitis B e antigen (HBeAg) seroconversion rates. In HBeAg negative patients, most of the patients would relapse after lamivudine has been discontinued. Pegylated interferon alpha-2a, an immunomodulatory agent, is a new drug that has just completed phase III clinical trials for the treatment of both HBeAg positive and HBeAg negative chronic HBV infection. The advantage of pegylated interferon alpha-2a in achieving sustained virological response over nucleoside-nucleotide analogs is particularly obvious in the HBeAg negative group. In both of these phase III studies, sustained off-treatment response is superior to the use of lamivudine. These recent data put pegylated interferon alpha-2a as the first choice of anti-HBV therapy, especially in young and motivated patients with chronic HBV infection.
authors: Department of Medicine, Caritas Medical Centre, Hong Kong SAR, China.
authors: Lawrence
authors: L
authors: Lai
authors: Chee-Kin
authors: CK
authors: Hui
authors: Nancy
authors: N
authors: Leung
authors: George K
authors: GK
authors: Lau
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D004337:Drug Carriers / Q000737:chemistry*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology*; D011092:Polyethylene Glycols / Q000737:chemistry*; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D004337:Drug Carriers; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C047910:interferon alpha 2, Ala(30,32,33)-; D011092:Polyethylene Glycols
references: N Engl J Med. 2004 Sep 16;351(12):1206-17
references: 15371578
references: Semin Liver Dis. 2004;24 Suppl 2:33-8
references: 15346244
references: Cancer. 1988 May 15;61(10):1942-56
references: 2834034
references: Hepatology. 1989 Nov;10(5):761-3
references: 2680866
references: Semin Liver Dis. 1989 Nov;9(4):249-53
references: 2690348
references: Am J Gastroenterol. 1993 Feb;88(2):212-6
references: 8424423
references: J Hepatol. 1995 Jun;22(6):696-9
references: 7560864
references: Ann Intern Med. 1993 Aug 15;119(4):312-23
references: 8328741
references: Gut. 1993;34(2 Suppl):S148-9
references: 8314487
references: N Engl J Med. 1996 May 30;334(22):1422-7
references: 8618580
references: Gastroenterology. 1997 Nov;113(5):1660-7
references: 9352870
references: N Engl J Med. 1997 Dec 11;337(24):1733-45
references: 9392700
references: N Engl J Med. 2005 Jun 30;352(26):2673-81
references: 15987916
references: N Engl J Med. 2005 Jun 30;352(26):2682-95
references: 15987917
references: Aliment Pharmacol Ther. 2006 Apr 15;23(8):1171-8
references: 16611278
references: Biochemistry. 2000 Sep 5;39(35):10634-40
references: 10978146
references: Drugs. 2000 Sep;60(3):517-31
references: 11030464
references: J Hepatol. 2000 Dec;33(6):998-1002
references: 11131465
references: Gastroenterology. 2001 Jul;121(1):101-9
references: 11438498
references: Clin Pharmacokinet. 2001;40(7):539-51
references: 11510630
references: BioDrugs. 2001;15(7):419-29
references: 11520253
references: J Viral Hepat. 2001 Sep;8(5):311-21
references: 11555188
references: Curr Pharm Des. 2002;8(24):2139-57
references: 12369859
references: Semin Liver Dis. 2002;22 Suppl 1:15-21
references: 12447725
references: J Hepatol. 2003;38 Suppl 1:S90-103
references: 12591188
references: Semin Liver Dis. 2003 Feb;23(1):81-8
references: 12616453
references: J Viral Hepat. 2003 Jul;10(4):298-305
references: 12823597
references: J Hepatol. 2003;39 Suppl 1:S172-6
references: 14708699
references: Lancet. 1987 Oct 17;2(8564):877-80
references: 2889081